These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 14617792)

  • 21. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
    Fang G; Chang BS; Kim CN; Perkins C; Thompson CB; Bhalla KN
    Cancer Res; 1998 Aug; 58(15):3202-8. PubMed ID: 9699642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
    Alas S; Bonavida B
    Cancer Res; 2001 Jul; 61(13):5137-44. PubMed ID: 11431352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
    Bonavida B; Vega MI
    Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM; Laugen C; Bonham L; Hackman RC; Hockenbery DM; Bhatt R; Hollenback D; Carew H; Singer JW; Press OW
    Clin Cancer Res; 2005 Jul; 11(13):4857-66. PubMed ID: 16000584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
    Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells.
    Ibrado AM; Liu L; Bhalla K
    Cancer Res; 1997 Mar; 57(6):1109-15. PubMed ID: 9067280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1 dependent.
    Burek M; Maddika S; Burek CJ; Daniel PT; Schulze-Osthoff K; Los M
    Oncogene; 2006 Apr; 25(15):2213-22. PubMed ID: 16288204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.
    Emmanouilides C; Jazirehi AR; Bonavida B
    Cancer Biother Radiopharm; 2002 Dec; 17(6):621-30. PubMed ID: 12537665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas.
    Zhang N; Khawli LA; Hu P; Epstein AL
    Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells.
    Chipuk JE; Bhat M; Hsing AY; Ma J; Danielpour D
    J Biol Chem; 2001 Jul; 276(28):26614-21. PubMed ID: 11320089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells.
    Perkins C; Kim CN; Fang G; Bhalla KN
    Cancer Res; 1998 Oct; 58(20):4561-6. PubMed ID: 9788601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
    Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells.
    Li ZM; Jiang WQ; Zhu ZY; Zhu XF; Zhou JM; Liu ZC; Yang DJ; Guang ZZ
    Cancer Biol Ther; 2008 Jan; 7(1):51-60. PubMed ID: 17938578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
    Byrd JC; Kitada S; Flinn IW; Aron JL; Pearson M; Lucas D; Reed JC
    Blood; 2002 Feb; 99(3):1038-43. PubMed ID: 11807010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl.
    Anto RJ; Mukhopadhyay A; Denning K; Aggarwal BB
    Carcinogenesis; 2002 Jan; 23(1):143-50. PubMed ID: 11756235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
    Smith MR; Joshi I; Jin F; Obasaju C
    BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.